CVS Health’s Breakup: A Turning Point for Pharma Supply Chains or a Redistribution of Market Power?

For nearly two decades, vertical integration has shaped the U.S. pharmaceutical supply chain. Pharmacy benefit managers (PBMs), insurers, specialty pharmacies and retail pharmacy networks increasingly became interconnected through common ownership.

The underlying proposition was straightforward: integrating financing, reimbursement, dispensing and patient services could improve coordination, reduce costs and create health care value.

CVS Health became a leading example of this strategy.

Its 2007 acquisition of Caremark integrated retail pharmacy operations with pharmacy benefit management. Its 2018 acquisition of Aetna extended that integration into health insurance.

On Nov. 4, 2026, CVS announced plans to separate into two publicly traded companies following a comprehensive strategic review.

The health care solutions company would retain Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health. The independent CVS Pharmacy company would operate approximately 9,000 retail pharmacies, mail pharmacy services, MinuteClinic and Health100.

The separation is expected in the first half of 2028, subject to customary conditions and final approvals.¹

The announcement raises an important question for pharmaceutical supply-chain executives. Does separating ownership change how efficiently medicines reach patients, or merely change which organizations capture the economic value generated along the supply chain?

Why Is CVS Breaking Up?

CVS’s financial performance provides important context.

According to its 2025 annual report, Pharmacy & Consumer Wellness revenue increased from $116.8 billion in 2023 to $139.4 billion in 2025. Prescription volume increased from approximately 1.65 billion to 1.81 billion prescriptions. However, profitability did not keep pace. The segment’s GAAP operating margin declined from 4.6% in 2023 to 3.5% in 2025. Its adjusted operating margin declined from 5.1% to 4.3%.²

These figures illustrate a central challenge in pharmaceutical distribution: increasing prescription volume and revenue does not necessarily translate into proportionate profitability. Retail pharmacies face pressure from reimbursement arrangements, drug acquisition costs, labor expenses, inventory requirements and changing consumer expectations.

Nevertheless, the separation cannot be explained simply as a response to financial deterioration. CVS reported third-quarter 2026 revenue of $108.4 billion, representing 5.4% year-over-year growth. Adjusted earnings per share increased to $2.09 from $1.60, and management raised its full-year earnings guidance.³

The company announced the separation while reporting improving financial performance. CVS’s stated rationale emphasizes greater strategic focus, independent capital allocation, operational agility and expanded commercial partnerships.¹

The businesses being separated also operate under fundamentally different economic models. Insurance profitability depends on premiums, medical claims and risk management. PBM performance depends on benefit administration, contracting and pharmacy services. Retail pharmacy profitability depends on prescription reimbursement, dispensing volume, inventory costs and physical operating infrastructure.

Common ownership can create efficiencies, but it can also constrain the flexibility of businesses with different investment requirements and competitive environments. The evidence therefore supports interpreting the breakup as a strategic reassessment of integration rather than proof that integration has failed.

Regulatory Scrutiny and the Limits of Integration

The separation also occurs amid increasing scrutiny of vertically integrated pharmaceutical intermediaries.

The Federal Trade Commission’s July 2024 interim staff report documented substantial PBM market concentration. According to the report, the three largest PBMs processed nearly 80% of U.S. prescriptions in 2023, while pharmacies affiliated with those PBMs accounted for nearly 70% of specialty drug revenue.⁴

The FTC raised concerns about the potential for vertically integrated PBMs to favor affiliated pharmacies and influence prescription drug access.

These findings provide important industry context, although they do not establish that regulatory pressure caused CVS’s separation.

Indeed, the proposed restructuring preserves integration among Aetna, Caremark and CVS Specialty. This is an important distinction. CVS is not abandoning vertical integration. It is selectively separating retail dispensing while retaining integration across insurance, pharmacy benefit management and specialty pharmacy services. The economic value of integration may differ substantially across pharmaceutical supply-chain functions.

Pharmaceutical Manufacturers: New Contracting Opportunities

An independent CVS Pharmacy could create additional opportunities for pharmaceutical manufacturers.

CVS has explicitly identified expanded partnerships with manufacturers, insurers and PBMs as a potential benefit of the separation.¹

A standalone pharmacy organization may have greater flexibility to negotiate arrangements involving prescription fulfillment, patient affordability, adherence programs and other services. This could be particularly relevant for pharmaceutical products facing significant patient-access barriers. GLP-1 medications illustrate the challenge.

Manufacturers must coordinate insurance coverage, patient affordability, inventory availability, dispensing and treatment continuity. A large independent pharmacy network could potentially support alternative fulfillment arrangements and manufacturer-sponsored patient services. However, manufacturers would still need to negotiate formulary placement, reimbursement and utilization management requirements with PBMs and insurers.

Greater distribution flexibility does not automatically produce greater access to insured patients. Manufacturers should therefore distinguish between securing market access and ensuring successful prescription fulfillment. The CVS separation may create additional opportunities in the latter without fundamentally changing the former.

Pharmaceutical Wholesalers: Will Distribution Economics Change?

The implications for pharmaceutical wholesalers deserve particular attention.

Cencora, Cardinal Health and McKesson perform essential functions involving pharmaceutical procurement, inventory management, distribution and fulfillment.

An independent CVS Pharmacy would remain a major distribution customer. However, the separation raises questions about purchasing arrangements, distribution contracts and operational coordination.

Will the two companies maintain coordinated procurement arrangements? Will existing wholesaler agreements continue under their current terms? Could retail and specialty pharmacy operations adopt different distribution-service models? These questions remain unresolved.

Potential areas affected include distribution-service agreements, inventory ownership, returns management, chargebacks, demand forecasting and data reporting.

For manufacturers, changes in contracting relationships could also influence the selection and management of distribution channels.

Nevertheless, separation does not necessarily mean that pharmaceutical purchasing volumes, wholesaler relationships or physical distribution networks will change. Existing agreements may continue, and operational changes will depend on transition arrangements.

The critical distinction is between changing who negotiates distribution contracts and changing the underlying efficiency of pharmaceutical distribution. A restructuring that redistributes negotiating leverage without reducing distribution costs or improving service reliability may change commercial outcomes without creating additional supply-chain value.

The Specialty Pharmacy Exception

Perhaps the most revealing feature of CVS’s restructuring is what remains integrated. CVS Specialty will continue operating alongside Caremark and Aetna.

Specialty pharmaceuticals frequently require complex benefit coordination, prior authorization, specialized handling, patient education and ongoing clinical support. Integration across these functions can potentially improve coordination and treatment continuity.

However, it can also create incentives that influence pharmacy selection, network participation and competition. The proposed separation therefore establishes different ownership arrangements for retail and specialty pharmaceutical distribution.

Retail dispensing becomes independent, while specialty dispensing remains integrated with insurance and benefit management. This raises a fundamental question. If separating PBM ownership from retail pharmacies is expected to improve competition, should similar competitive considerations be examined in specialty pharmaceutical distribution?

There may be legitimate operational reasons for maintaining specialty integration. Nevertheless, those benefits should be evaluated through measurable improvements in distribution efficiency, treatment continuity, patient affordability and clinical outcomes.

The appropriate question is not whether integration is inherently beneficial or harmful. It is whether integration produces demonstrable health care value.

Community Pharmacy: Independence Does Not Guarantee Sustainability

The separation also raises questions about community pharmacy economics. An independent CVS Pharmacy would gain strategic flexibility but would still face reimbursement pressure, labor expenses, inventory costs and competition from alternative dispensing channels.

Further store consolidation is possible, although CVS has not established that the separation itself will require additional closures.

From a supply-chain perspective, fewer dispensing locations do not necessarily mean lower total costs. Store closures may reduce operating expenses but increase travel distances, delivery requirements and disruptions in medication access.

These consequences may be particularly significant for older adults, patients managing chronic conditions and communities with limited pharmacy alternatives.

Independent pharmacies could potentially benefit from reduced ownership-related conflicts between Caremark and CVS Pharmacy. However, separation does not automatically change reimbursement rates, pharmacy network requirements or other economic pressures.

The competitive consequences will depend on the commercial terms under which pharmacies operate.

Supply-Chain Data: A Less Visible Consequence

Pharmaceutical supply chains depend on timely information about prescription demand, inventory availability, reimbursement, dispensing and patient treatment patterns. Within integrated organizations, some information can be coordinated through internal systems.

Following separation, certain exchanges may require formal agreements between independent companies. This could increase requirements involving interoperability, data governance, privacy and cybersecurity.

Manufacturers seeking to evaluate medication adherence or patient-support programs may also need information from multiple commercial partners. However, separation could encourage more standardized and transparent data-sharing arrangements. The objective should be to preserve supply-chain visibility without requiring common ownership.

For manufacturers and distributors, data interoperability may become as strategically important as physical distribution capacity.

Three Tests for Evaluating the Breakup

The consequences of CVS’s restructuring should not be judged solely by shareholder returns or corporate operating margins. Three tests would provide a more meaningful assessment.

First, does competition improve? Relevant indicators include pharmacy network participation, reimbursement arrangements, manufacturer contracting opportunities and prescription volume across dispensing channels. Creating two independent companies does not, by itself, establish that competition has improved.

Second, does supply-chain efficiency improve? Potential benefits include more focused management, greater procurement flexibility and stronger incentives for operational innovation. Potential costs include duplicated administrative functions, additional contracting requirements, fragmented information systems and reduced coordination. Relevant indicators include inventory turnover, distribution expenses, fulfillment reliability, stockouts and dispensing costs. A reduction in one company’s expenses should not automatically be interpreted as a reduction in total supply-chain costs.

Third, do patients experience better access? Does the restructuring improve prescription affordability and medication availability? Do patients experience fewer prescription abandonment events, fewer treatment interruptions and better continuity of care? Does the pharmacy network remain accessible in underserved communities? These outcomes provide a more meaningful assessment of whether restructuring creates health care value.

Beyond Ownership: Who Controls Access to Medicines?

CVS’s proposed breakup represents an important development in the evolution of pharmaceutical distribution. The financial evidence suggests that the restructuring is not simply a response to declining retail pharmacy performance. Rather, it reflects a reassessment of where common ownership creates strategic and economic value.

The continued integration of Caremark, Aetna and CVS Specialty demonstrates that vertical integration is not disappearing. Instead, different segments of the pharmaceutical supply chain may evolve toward different combinations of integration and independence.

For manufacturers, wholesalers, PBMs and pharmacies, the central challenge is ensuring that changing organizational structures improve performance rather than merely redistribute economic value.

Manufacturers develop and produce medicines. PBMs and insurers influence coverage, reimbursement and patient access. Wholesalers and pharmacies coordinate physical distribution and dispensing. Changing ownership at one stage does not necessarily change the incentives or market power operating at another.

The ultimate measure of pharmaceutical supply-chain performance is not simply how efficiently medicines are purchased, distributed or reimbursed. It is whether those activities enable patients to obtain and continue the treatments they need.

CVS’s breakup may change who owns the pharmacy. The more consequential question is whether it changes who controls access to medicines and whether patients ultimately benefit.

Thani Jambulingam, Ph.D., is a professor of food, pharma and healthcare business at Saint Joseph’s University’s Haub School of Business.

References

1. CVS Health. CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare. November 4, 2026. Accessed November 10, 2026. https://www.cvshealth.com/news/company-news/cvs-health-announces-intent-to-create-two-distinct-leaders-in-healthcare.html

2. CVS Health Corporation. Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2025. Pharmacy & Consumer Wellness segment financial and operating results. Accessed November 10, 2026. https://s206.q4cdn.com/752775519/files/doc_financials/2025/ar/2025-Annual-Report.pdf

3. CVS Health Corporation. CVS Health Corporation Reports Third Quarter 2026 Results and Raises Full-Year 2026 Guidance. November 4, 2026. Accessed November 10, 2026. https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-third-quarter-2026-results-and-raises-full-year-2026-guidance.html

4. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim Staff Report. July 2024. Accessed November 10, 2026. https://www.ftc.gov/reports/pharmacy-benefit-managers-report